Nonsynthetic platelet-like products: methods and clinical potential in hemorrhage control

Uncontrolled bleeding remains a leading cause of preventable death in trauma, and military medicine, underscoring the critical need for effective, accessible available hemostatic agents. While conventional platelet transfusions are indispensable for promoting primary hemostasis, they present several limitations, including short shelf life, logistical challenges, and transfusion-related risks. This review of evidence was done to obtain state-of-the-art data in this field. Hence, this scoping review pays to nonsynthetic platelet-like products, such as platelet microparticles and lyophilized platelet derivatives, which have emerged with promising hemostatic properties. Platelet microparticles, derived from activated platelets, exhibit potent procoagulant activity by contributing to both intrinsic and extrinsic coagulation pathways. Lyophilized platelet products, exemplified by thrombosomes, offer extended shelf life, room-temperature stability, and rapid hemostatic action, making them particularly valuable in prehospital and austere environments. Platelet lysate and PRF, while predominantly explored in regenerative medicine, have under-investigated potential as topical hemostatic agents. Despite encouraging preclinical and early clinical data for some of these products, challenges remain in terms of scalability, regulatory approval, and standardized clinical evaluation. Further research, particularly into platelet lysate and PRF, is warranted to validate their role in hemorrhage control. Nonsynthetic platelet-like products may represent a transformative approach in the management of life-threatening bleeding.